1
Manuscript. Ethics approval and consent to participate The pancreatic TMA as well as pancreatic cancer biospecimens transferred under a Material Transfer Agreement (MTA) to NCI was approved by the Office of Human Subjects Research at the NIH and was found exempt from IRB review because it contained patient de-identified information. Consent for publication Not applicable. Competing interests The a
1
Rody JR, Rocha FG, Jia XY, Qin LX, D'Angelica MI, DeMatteo RP, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and Mesothelin as biomarkers. PLoS One. 2012;7(7):10. 5. Jones S, Zhang XS, Parsons DW, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analy
1
Eimling A, Bonzheim I, Staebler A, Fend F. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44(3):329?5. Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y, Bruns C, Kirchner T, Knosel T. Desmogleins as prognostic biomarkers in res
1
Ning (scored by 0, 1+, 2+, and 3+ intensity levels) compared to pancreatic cancers with cytoplasmic CNKSR1 staining only (Mann Whitney U test; 2-tailed). d Cytoplasmic CNKSR1 expression levels (scored semiquantitatively as 0, 1+, 2+, and 3+) and nuclear p-ERK expression levels (scored as positive cells) (Pearson's correlation coefficient test; 2-tailed). e Kaplan-Meier survival analysis of pancr
1
Eimling A, Bonzheim I, Staebler A, Fend F. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44(3):329?5. Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y, Bruns C, Kirchner T, Knosel T. Desmogleins as prognostic biomarkers in res
1
Opathol Exp Neurol 2008, 67:456?69. Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, Kiss R: Galectin-1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma25.26.27.28.29.30.31. 32.33.34.35.36.37.38.39.40.41.42. 43. 44.model are partly mediated through the control of BEX2 expression. Neoplasia 2009, 1
1
Activation of ERK with induction of apoptosis by various chemopreventive and chemotherapeutic agents [39-41]. In fact, oxidants have been shown to activate ERK by taking over the growth factor receptor signaling pathways [42-46]. Moreover, ERK may get activated in response to DNA damage and can phosphorylate p53 in vitro [23,24,47-49]. We found that exposure of Capan-2 or BxPC-3 cells with apoptos
1
By the ample amount of normal mouse brain tissue available for dissection. In spite of species differences, cross-hybridization of mouse genetic material to human probes did prove to be a common occurrence. These data made it possible to control, rather stringently, for the potential contamination of tumor edge samples with mouse brain. Of course, there could still be possible contamination ?react